# Huatainuo Biology

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/huatainuo-biology

- Industry: Pharmaceuticals
- Headquarters: Beijing, China
- Website: www.varnotech.com.cn
- Total disclosed funding: $103M
- Latest round: Series B (Mar 22, 2024)
- Investors on record: 10

## About

Based in Beijing, China and established in 2019, Huatainuo Biology is a biotechnology company that develops vaccine. The company has partnerships with Chengda Biotechnology, Beijing Kangleweishi Biotechnology Co., Ltd. and Ab&B Bio-Tech Co., Ltd. The company has its headquarters and R&D center in Beijing, a new adjuvant production facility in Chengdu, and a vaccine production facility in Taizhou. As of 2024, the company has nearly 30 tons of raw materials for adjuvant production and can produce nearly 30 varieties of new adjuvants. In March 2024, it raised a series B funding for CNY 600 million.

The company is dedicated to the development and industrialization of human vaccine products and innovative adjuvants. The company's self-developed products such as peptide therapeutic vaccine HN201, recombinant protein vaccine HN101, and broad-spectrum recombinant protein vaccine HN103. Its products are used to treat Covid-19, influenza, malaria and shingles, and so on.

The company will use the series B funding for the advancement of clinical trials for the pipeline of herpes zoster vaccine and influenza vaccine, as well as the construction of vaccine production bases and adjuvant production bases.

## Funding rounds

- Series B, Mar 22, 2024, $83M — 3E Bioventures Capital, Shunxi Fund, Kinsight Capital, Watere Capital, Taizhou Huayin Gold Investment, Beijing Jingguoguan Real Estate Management
- Series A, Mar 8, 2021, $20M — IDG Capital, Legend Star, Moom Group, FC Capital - China

## Investors

- IDG Capital (https://capitalatlas.ai/funds/idg-capital) — Series A
- Legend Star (https://capitalatlas.ai/funds/legend-star) — Series A
- Moom Group — Series A
- FC Capital - China (https://capitalatlas.ai/funds/fc-capital-china) — Series A
- 3E Bioventures Capital (https://capitalatlas.ai/funds/3e-bioventures-capital) — Series B
- Shunxi Fund (https://capitalatlas.ai/funds/shunxi-fund) — Series B
- Kinsight Capital (https://capitalatlas.ai/funds/kinsight-capital) — Series B
- Watere Capital (https://capitalatlas.ai/funds/watere-capital) — Series B
- Taizhou Huayin Gold Investment — Series B
- Beijing Jingguoguan Real Estate Management — Series B